8-K: Xtant Medical Divests Coflex/CoFix and International Hardware Businesses for $19.2 Million, Bolstering Balance Sheet

Xtant Medical Holdings, Inc. has entered into definitive agreements to sell its Coflex and CoFix spinal implant assets and all international hardware businesses to Companion Spine, LLC for a total consideration of $19.2 million, aiming to reduce debt and enhance liquidity.

Summary

• Xtant Medical Holdings, Inc. and its subsidiary Surgalign SPV, Inc. (collectively, the Seller) entered into an Asset Purchase Agreement with Companion Spine, LLC (Buyer) to sell certain Coflex and CoFix products in the United States (Coflex/CoFix Business) for $17.5 million.
• Concurrently, Xtant Medical and its subsidiary Paradigm Spine GmbH entered into an Equity Purchase Agreement with Companion Spine, LLC to sell all equity shares of Paradigm Spine GmbH (international hardware business) for $1.7 million.
• The total purchase price for both transactions is $19.2 million.
• The Coflex/CoFix Business purchase price includes a $2.5 million non-refundable cash deposit paid upon execution, with up to two additional $2.5 million cash deposits possible if the Buyer requires more time to secure financing.
• The remaining balance of the Coflex/CoFix purchase price will consist of a cash payment of up to $6.8 million (if additional deposits are not made) and an $8.2 million unsecured promissory note, maturing on December 31, 2025.
• The international hardware business purchase price is subject to certain cash, indebtedness, and net working capital adjustments.
• Completion of both transactions is contingent on each other closing simultaneously and is subject to Companion Spine obtaining financing.
• The closings are expected to occur in the third quarter of 2025.
• Xtant Medical and certain subsidiaries entered into Limited Consent Agreements with MidCap Financial Trust and MidCap Funding IV Trust, consenting to the transactions and requiring a prepayment of $9.6 million to MidCap from the proceeds.
• The $9.6 million prepayment to MidCap includes an initial $2.5 million from the signing date deposit, an additional $2.5 million from subsequent deposits/Seller Note payments, and 50% of further amounts received until an additional $4.6 million is reached.
• Xtant Medical will be subject to a three-year non-compete clause for the Coflex Business worldwide and Fourth Dimension Spine Systems in the US, and a two-year non-solicitation clause for transferred employees.

Sentiment

Score: 7

Explanation: The divestiture is a positive strategic move for Xtant Medical, allowing it to focus on higher-margin core businesses and reduce debt. While there are risks associated with the buyer's financing and the unsecured note, the overall intent and immediate financial benefits (debt reduction, liquidity) are favorable. The non-compete is standard for such sales.

Positives

• The transaction provides Xtant Medical with $19.2 million in total consideration, significantly strengthening its balance sheet.
• Proceeds will be used to reduce long-term debt by $9.6 million and provide additional cash liquidity.
• The divestiture allows Xtant Medical to enhance its focus on higher-margin, best-in-class orthobiologics, streamlining operations.
• The Coflex and CoFix franchises, along with HPS and related spinal fixation technologies, are expected to be in capable hands with Companion Spine and Viscogliosi Brothers, who have a proven track record in the neuro-musculoskeletal space.

Negatives

• The completion of the transactions is subject to Companion Spine obtaining financing, which introduces uncertainty and potential for delay or termination.
• A significant portion of the consideration ($8.2 million) is in the form of an unsecured promissory note, which carries the risk of non-payment by the Buyer.
• The transaction involves the potential for diversion of management's attention from core business operations.
• There is a risk of potential loss of key Company employees, suppliers, customers, and distributors as a result of the announcement and/or completion of the transactions.
• The non-compete clause restricts Xtant Medical from engaging in the Coflex Business worldwide and Fourth Dimension Spine Systems in the US for three years, and a two-year non-solicitation of transferred employees.

Risks

• Delays in completing the Coflex/CoFix Transaction and the Paradigm Transaction within the expected time period, or the risk that the Transactions may not be completed at all, including if the Buyer is unable to obtain sufficient financing.
• The closing of each transaction is contingent upon the other, meaning failure of one could terminate both.
• Diversion of management's attention to complete the Transactions and from the Company's existing core business.
• Potential loss of key Company employees, suppliers, customers, distributors, and independent sales agents or other adverse effects on existing business relationships.
• Adverse impact on the Company's business, financial condition, and operating results if the Transactions are not completed, or if completed, do not achieve the anticipated effects, revenue, earnings, cost or revenue savings, or other financial results projected.
• Incurrence of more transaction costs than initially anticipated, which would reduce net proceeds.
• Failure of the Buyer to pay off the $8.2 million promissory note to be issued at the closing of the Coflex/CoFix Transaction.
• Adverse impact on the Company's business, particularly its Coflex/CoFix Business and international hardware business, if the agreements are terminated.
• Inaccurate assessment of unanticipated costs and liabilities associated with the Transactions, including potential litigation and adverse tax consequences.
• Incorrect accounting treatment of or estimates made in the accounting for the Transactions.
• General risks described in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent SEC filings.

Future Outlook

The transactions are expected to close in the third quarter of 2025, contingent on Companion Spine obtaining financing. Xtant Medical anticipates using the proceeds to reduce long-term debt and improve liquidity, allowing for an enhanced focus on its core orthobiologics business. Companion Spine expects the acquisition to significantly strengthen its product portfolio and global presence in spine care.

Management Comments

• Sean Browne, President and CEO of Xtant Medical: "This transaction is a significant step for us as we focus on our core business the development of higher-margin, best-in-class orthobiologics while also strengthening our balance sheet and streamlining our operations."
• Sean Browne: "At the same time, these franchises will be in great hands given the Viscogliosi Brothers proven track record of successful commercial execution in the neuro-musculoskeletal space."
• Sean Browne: "We believe they, along with Companion Spine, are the ideal partners to continue driving the growth of Coflex, CoFix, HPS, and related spinal fixation technologies."
• Sean Browne: "This transaction places Paradigm Spine with a team of people who are well-equipped to complete the remaining clinical and regulatory work and take these fantastic technologies to the next level."
• Anthony G. Viscogliosi, Principal at Viscogliosi Brothers, LLC, and Co-founder, Executive Chairman and CEO of Companion Spine: "The addition of these spine implant solutions will significantly strengthen Companion Spine's product solutions portfolio, reinforcing our commitment to innovation and excellence in spine care."
• Anthony G. Viscogliosi: "We are confident this will position us to better serve the needs of pain management physicians, spine surgeons, and their patients on a global scale, strengthening specifically our presence in the U.S."
• Anthony G. Viscogliosi: "This acquisition will position us as the largest posterior and cervical dynamic stabilization franchise business in the world."

Industry Context

This divestiture by Xtant Medical reflects a strategic shift towards higher-margin orthobiologics, a common trend in the medical technology sector where companies often streamline portfolios to focus on core competencies and improve profitability. The acquisition by Companion Spine, a Viscogliosi Brothers portfolio company, indicates continued consolidation and specialization within the neuro-musculoskeletal and spine care markets, with firms like Viscogliosi Brothers actively building comprehensive solution portfolios through strategic acquisitions.

Comparison to Industry Standards

• The transaction's structure, involving an upfront cash payment and a significant unsecured promissory note, is a common financing mechanism in M&A, particularly when the buyer's financing is contingent or when the seller retains some exposure to the buyer's future performance.
• The non-compete and non-solicitation clauses are standard in asset sales to protect the buyer's acquired business value and employee base.
• The required debt prepayment to MidCap Financial is typical for companies with existing credit agreements, where asset sales trigger mandatory prepayments to reduce secured debt.

Legal Proceedings

• The Company is supplementing its risk factors to include potential litigation and adverse tax consequences associated with the Transactions.

Stakeholder Impact

• Shareholders: Expected to benefit from debt reduction, improved liquidity, and a more focused business strategy on higher-margin orthobiologics.
• Employees: Certain members of Xtant's U.S. and international commercial organizations are expected to transition to Companion Spine, but there is a risk of potential loss of key employees if not transitioned or if relationships are adversely affected.
• Customers: The transition of products to Companion Spine is intended to ensure continued support, but changes in business relationships could occur.
• Suppliers: Potential adverse effects on existing business relationships with suppliers.
• Creditors (MidCap): Will receive a significant prepayment of $9.6 million, reducing Xtant's outstanding debt obligations to them.

Next Steps

• Companion Spine to obtain financing for the transactions.
• Closing of the Coflex/CoFix Asset Purchase Agreement and the Paradigm Spine GmbH Equity Purchase Agreement to occur simultaneously, expected in the third quarter of 2025.
• Xtant Medical to prepay $9.6 million to MidCap from the transaction proceeds.
• Xtant Medical to provide a further update on this transaction during its regularly scheduled second quarter results conference call in August.

Key Dates

Keywords

Xtant Medical, XTNT, Companion Spine, Divestiture, Asset Sale, Coflex, CoFix, Spinal Implants, International Business, Paradigm Spine GmbH, Orthobiologics, Debt Reduction, Liquidity, Medical Technology, Spine Care, Neuro-musculoskeletal, Unsecured Promissory Note, SEC Filing, Form 8-K